title: [Neurotoxicity of weekly TP (weekly paclitaxel + consecutive low-dose CDDP) therapy].
abstract: OBJECTIVE
  To evaluate drug-induced neurotoxicity with combination consecutive low-dose CDDP (CLD-CDDP) and weekly paclitaxel in comparison with TJ therapy. Neurotoxicity was judged according to accumulative scores on questionnaires.
  
  
  METHODS
  Weekly TP therapy (CDDP: 10 mg/m2, days 1-7, paclitaxel: 60-80 mg/m2, days 1, 8, 15) and TJ therapy (paclitaxel: 170-180 mg/m2, 3 hours, carboplatin AUC 4-5) were given to 24 subjects in 57 courses and 19 subjects in 30 courses as previously reported, respectively.
  
  
  RESULTS
  1. Significant differences were found in numbness accumulative scores (p = 0.011) between weekly TP and TJ therapy, but not in pain accumulative scores (p = 0.926) between weekly TP and TJ therapy. 2. Peak pain at days 3-4 of paclitaxel that appeared during TJ therapy disappeared during weekly TP therapy, while numbness persisted to a lesser extent with weekly TP therapy than with TJ therapy. 3. Numbness was observed to accumulate in some subjects but not in others during weekly TP therapy.
  
  
  CONCLUSIONS
  The patients' subjective symptoms were able to be objectively evaluated with the questionnaires. Weekly paclitaxel was observed to reduce neurotoxicity, which might be reinforced in combination with CDDP.
authors.affiliation: Dept. of Gynecology, Cancer Institute Hospital.
authors.forename: Shinichi
authors.initials: S
authors.lastname: Tate
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Hirai
authors.forename: Hideaki
authors.initials: H
authors.lastname: Iwasaki
authors.forename: Hideo
authors.initials: H
authors.lastname: Matsui
authors.forename: Soei
authors.initials: S
authors.lastname: Sekiya
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Hasumi
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D018771:Arthralgia / Q000139:chemically induced*; D016190:Carboplatin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006930:Hyperalgesia / Q000139:chemically induced*; D018482:Muscle, Skeletal / Q000502:physiology; D009135:Muscular Diseases / Q000139:chemically induced; D010051:Ovarian Neoplasms / Q000188:drug therapy; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D010147:Pain Measurement; D011795:Surveys and Questionnaires
chemical_list: D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin